Source: Annual Congress 2002 - Lung cancer: treatment
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. Vansteenkiste, R. Natale, G. Giaccone, R. Herbst, A. Feyereislova, A. Kay, M. Wolf (Leuven, Belgium; Beverly Hills, Houston, Wilmington, United States Of America; Amsterdam, The Netherlands; Macclesfield, United Kingdom). Two randomised, double-blind studies of ZD1839 in 425 patients with pretreated advanced non-small-cell lung cancer (IDEAL 1 and IDEAL 2). Eur Respir J 2002; 20: Suppl. 38, 2537

Member's Comments

No comment yet.

Related content which might interest you: Bevacizumab as first line treatment for advanced non-small cell lung cancer (NSCLC): a meta-analysis of randomised placebo-controlled trials (RCTs) Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial Source: Eur Respir J 2007; 30: Suppl. 51, 240s Year: 2007 The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003 LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 A three-arm phase III randomised trial assessing, in patients with extensive-disease (ED) small-cell lung cancer (SCLC), accelerated chemotherapy with the support of haematological growth factor or of oral antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001 A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily at 1250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Phase II study of cisplatin-vinorelbine sequenced by gemcitabine-vinorelbine in patients with unresectable non-small-cell lung cancer (NSCLC): preliminary results Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007 Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Cost-effectiveness analysis of three strategies of erlotinib treatment in non small-cell lung cancer: A prospective multicentric French study (ERMETIC) Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010